Integration of Antibody Array Technology into Drug Discovery and Development

被引:7
作者
Huang, Wei [1 ]
Whittaker, Kelly [2 ]
Zhang, Huihua [1 ]
Wu, Jian [3 ]
Zhu, Si-Wei [1 ]
Huang, Ruo-Pan [1 ,2 ,4 ]
机构
[1] Raybiotech Inc, Guangzhou, Guangdong, Peoples R China
[2] RayBiotech Inc, 3607 Pkwy Lane, Norcross, GA 30092 USA
[3] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China
[4] South China Biochip Res Ctr, Guangzhou, Guangdong, Peoples R China
关键词
antibody array; biomarker; drug discovery; protein target; GROWTH-FACTOR RECEPTOR; PHASE PROTEIN MICROARRAYS; BREAST-CANCER CELLS; TUMOR MICROENVIRONMENT; IN-VITRO; MULTIDRUG-RESISTANCE; PROTEASOME INHIBITOR; MULTIPLEXED ANALYSIS; PROFILING ARRAYS; HIGH-PERFORMANCE;
D O I
10.1089/adt.2017.808
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Antibody arrays represent a high-throughput technique that enables the parallel detection of multiple proteins with minimal sample volume requirements. In recent years, antibody arrays have been widely used to identify new biomarkers for disease diagnosis or prognosis. Moreover, many academic research laboratories and commercial biotechnology companies are starting to apply antibody arrays in the field of drug discovery. In this review, some technical aspects of antibody array development and the various platforms currently available will be addressed; however, the main focus will be on the discussion of antibody array technologies and their applications in drug discovery. Aspects of the drug discovery process, including target identification, mechanisms of drug resistance, molecular mechanisms of drug action, drug side effects, and the application in clinical trials and in managing patient care, which have been investigated using antibody arrays in recent literature will be examined and the relevance of this technology in progressing this process will be discussed. Protein profiling with antibody array technology, in addition to other applications, has emerged as a successful, novel approach for drug discovery because of the well-known importance of proteins in cell events and disease development.
引用
收藏
页码:74 / 95
页数:22
相关论文
共 156 条
[1]   Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer [J].
Aghajanian, C ;
Dizon, DS ;
Sabbatini, P ;
Raizer, JJ ;
Dupont, J ;
Spriggs, DR .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5943-5949
[2]   Progress in protein and antibody microarray technology [J].
Angenendt, P .
DRUG DISCOVERY TODAY, 2005, 10 (07) :503-511
[3]   Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels [J].
Arning, M ;
Kliche, KO ;
HeerSonderhoff, AH ;
Wehmeier, A .
MYCOSES, 1995, 38 (11-12) :459-465
[4]   Developing recombinant antibodies for biomarker detection [J].
Baird, Cheryl L. ;
Fischer, Christopher J. ;
Pefaur, Noah B. ;
Miller, Keith D. ;
Kagan, Jacob ;
Srivastava, Sudhir ;
Rodland, Karin D. .
CANCER BIOMARKERS, 2010, 6 (5-6) :271-279
[5]   Properties and identification of human protein drug targets [J].
Bakheet, Tala M. ;
Doig, Andrew J. .
BIOINFORMATICS, 2009, 25 (04) :451-457
[6]  
Belov L, 2001, CANCER RES, V61, P4483
[7]  
Bettazzi F, 2013, BIOANALYSIS, V5, P11, DOI [10.4155/BIO.12.293, 10.4155/bio.12.293]
[8]   Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer [J].
Bharadwaj, U. ;
Eckols, T. K. ;
Kolosov, M. ;
Kasembeli, M. M. ;
Adam, A. ;
Torres, D. ;
Zhang, X. ;
Dobrolecki, L. E. ;
Wei, W. ;
Lewis, M. T. ;
Dave, B. ;
Chang, J. C. ;
Landis, M. D. ;
Creighton, C. J. ;
Mancini, M. A. ;
Tweardy, D. J. .
ONCOGENE, 2015, 34 (11) :1341-1353
[9]   Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease [J].
Bjorkqvist, Maria ;
Ohlsson, Mattias ;
Minthon, Lennart ;
Hansson, Oskar .
PLOS ONE, 2012, 7 (01)
[10]   Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study [J].
Blackwell, Kimberly L. ;
Burstein, Harold J. ;
Storniolo, Anna Maria ;
Rugo, Hope S. ;
Sledge, George ;
Aktan, Gursel ;
Ellis, Catherine ;
Florance, Allison ;
Vukelja, Svetislava ;
Bischoff, Joachim ;
Baselga, Jose ;
O'Shaughnessy, Joyce .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2585-2592